KROMATID Blog
2025: A Pivotal Year for Genomic Insight - and What Comes Next in 2026 Allogeneic Cell Therapy Cell and Gene Therapy Despite numerous challenges, the cell and gene therapy (CGT) sector has never moved faster. In 2025, we saw breakthroughs in precision editing, rapid scale-up of manufacturing platforms, and renewed investor attention on therapies with clear clinical differentiation. But alongside the scientific momentum, one theme stood out more than any other: genomic stability is now a defining hallmark for safety, reproducibility, and regulatory confidence.
Ensuring Genomic Integrity in Allogeneic Cell Therapy Development Genomic Integrity CAR-NK Therapy Allogeneic Cell Therapy Cell and Gene Therapy iPSC Therapy CAR-T Ensuring Genomic Integrity in Allogeneic Cell Therapy Development
Sorry, but there are no results that match your current filters and search.
Please try a different filter combination.

Stay Updated with the Latest in Next Gen Cytogenetics.

Subscribe to our blog and get:

  • Industry Insights - The latest trends shaping the biotech world.
  • Expert Advice - Learn from proven industry leaders on regulations and compliance.
  • Exclusive Updates - Be informed on new projects, products, and services.